Latest Breaking News On - Jacky vonderscher - Page 1 : comparemela.com

ENYO Pharma Announces a 39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome

ENYO Pharma ENYO announced that it has received clearance of its Investigational New Drug IND application from the U.S. Food and Drug Administration FDA to initiate a Phase 2 clinical study of Vonafexor a highly selective FXR agonist for the treatment of Alport Syndrome.

Bpifrance innobioJacky vonderscherDrug administrationEuropean medicines agencyAlport syndromeInvestigational new drugBusiness wireAutosomal dominant polycystic kidney diseaseMorningside venturesAndera partnersBpifrance largeChronic kidney diseaseOrphan drug designationIain dukesMedia contactRelations enyopharma

ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome

ENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport Syndrome
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Annie florence loyerJacky vonderscherBpifrance innobioDrug administrationEuropean medicines agencyAlport syndromeInvestigational new drugBusiness wireAutosomal dominant polycystic kidney diseaseMorningside venturesAndera partnersBpifrance largeChronic kidney diseaseOrphan drug designationIain dukesFlorence loyer

ENYO Pharma Announces Two Vonafexor Data Presentations at AASLD The Liver Meeting

Press release content from Business Wire. The AP news staff was not involved in its creation.

United statesJacky vonderscherPietro scalfaroAnnie florence loyerStephen harrisonClinical research networkLiver meetingAmerican associationLiver diseasesInvestigator pr stephen harrisonLate breaking sessionChief executive officerBile acidNon alcoholic steato hepatitisResearch networkProspective study

ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients

ENYO Pharma Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Chang gung memorial hospitalTaoyuan xianJacky vonderscherKostenloser wertpapierhandelPietro scalfaroAnnie florence loyerChao wei hsuFrench infectiology research centerDrug safety monitoring committeeNon alcoholic steato hepatitisLower limit of quantificationAlanine aminotransferaseAspartate aminotransferaseChief executive officerBile acidFlorence loyer

ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks

ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJacky vonderscherStephena harrisonKostenloser wertpapierhandelPietro scalfaroAnnie florence loyerPinnacle clinical researchFrench infectiology research centerAlcoholic steato hepatitisPrincipal investigatorMedical directorPinnacle clinicalChief executive officerNon alcoholic steato hepatitisBile acidFlorence loyer